FLT3 inhibitor

1 marketed 2 in Phase 3

This page covers all FLT3 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting FLT3 (FMS-like tyrosine kinase 3), FLT3.

Targets

FLT3 (FMS-like tyrosine kinase 3) · FLT3

Marketed (1)

Gilteritinib (GILT) · Technische Universität Dresden · Oncology
Gilteritinib is a tyrosine kinase inhibitor that selectively targets FLT3 (FMS-like tyrosine kinase 3) to inhibit proliferation of acute myeloid leukemia cells.

Phase 3 pipeline (2)

CGT9486 · Cogent Biosciences, Inc. · Oncology
CGT9486 is a selective tyrosine kinase inhibitor that targets FLT3, a receptor implicated in acute myeloid leukemia and other hematologic malignancies.
ICP-488 · Beijing InnoCare Pharma Tech Co., Ltd. · Oncology
ICP-488 is a tyrosine kinase inhibitor that targets FLT3 and other kinases involved in hematologic malignancies.